Market Scrutiny Deepens for Healthcare Companies Delcath Systems and Curaleaf

Delcath Systems, Inc. and Curaleaf are both healthcare companies currently facing market scrutiny. Independent reports compare the two businesses across various metrics, including profitability, analyst ratings, and valuation. Delcath Systems has lower revenue but higher earnings per share than Curaleaf, while Curaleaf trades at a lower price-to-earnings ratio.

The companies exhibit different market profiles: Delcath Systems benefits from strong institutional backing, with 61.1% of its shares held by institutions and 19.4% held by company insiders. Conversely, Curaleaf has zero institutional ownership but carries a higher share price volatility with a beta of 1.57.